In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.
about
Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations.Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.A Review of the Efficacy and Safety of Genvoya(®) (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.Protecting bone in long-term HIV positive patients receiving antiretrovirals.Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.HIV-hepatitis B virus co-infection: epidemiology, pathogenesis, and treatment.Effects of a Nutritional Protein-Rich Drink on the Pharmacokinetics of Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide, and Tenofovir Compared With a Standard Meal in Healthy Japanese Male Subjects.Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.Analysis of hepatitis B virus genotype changes in patients with chronic hepatitis B infection on tenofovir therapy.Role of tenofovir alafenamide in the jungle of antiretroviral prescription.Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection.
P2860
Q36076011-F2492BB5-D88C-490D-BB67-E5762BFD1F11Q36275141-D4D618F0-2167-4FC4-AD3A-3B120DB1AE98Q36934918-2CDEC034-4D53-4DB4-8CE2-CCF4C2704D88Q38756133-E890FC51-EBCB-4E9C-922B-6E33835F25B5Q38836871-EB9C7582-F2B4-46E8-9F26-CF317C38E458Q38836878-B9B8C099-F5B7-4D7E-8FCF-BA46E851D8D7Q39002230-69073CA5-B3AF-452D-A18A-EB5B0C01D14AQ39425755-6563B1CF-0D5A-4E9F-94EA-CE1ACA2A0E90Q40185119-A8203166-48E5-4A3C-B8E4-F802CA0A4C9FQ40785692-C3A617A1-ACE2-4B2C-8871-212363EC5846Q40799373-4AD9E4D2-8293-431F-A4D0-F4B1BCB54830Q50080891-B24E4F2A-DC54-4A44-9579-8567C2C5A598Q52374199-4635D0E0-8677-42F2-B390-4B44E70F3DBA
P2860
In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
In Vitro Virology Profile of T ...... Tenofovir Disoproxil Fumarate.
@ast
In Vitro Virology Profile of T ...... Tenofovir Disoproxil Fumarate.
@en
type
label
In Vitro Virology Profile of T ...... Tenofovir Disoproxil Fumarate.
@ast
In Vitro Virology Profile of T ...... Tenofovir Disoproxil Fumarate.
@en
prefLabel
In Vitro Virology Profile of T ...... Tenofovir Disoproxil Fumarate.
@ast
In Vitro Virology Profile of T ...... Tenofovir Disoproxil Fumarate.
@en
P2093
P2860
P356
P1476
In Vitro Virology Profile of T ...... Tenofovir Disoproxil Fumarate.
@en
P2093
Christian Callebaut
George Stepan
Michael D Miller
P2860
P304
P356
10.1128/AAC.01152-15
P407
P577
2015-07-06T00:00:00Z